INTRODUCTION
In the initial step of angiogenesis, mural cells overlying endothelial cells (ECs) dissociate from them, and the ECs start to migrate and proliferate.
1 Therefore, at the onset of angiogenesis, regulators associated with blood vessel maintenance need to be transiently suppressed. ECs proliferate on stimulation with growth factors, especially vascular endothelial growth factor (VEGF), while simultaneously such factors induce upregulation of molecular cues that disrupt blood vessel stability. 2 However, expression of such molecules does not persist for the whole period of growth and maturation of blood vessels during angiogenesis.
For stabilization of blood vessels under normoxia, mural cells such as pericytes or vascular smooth muscle cells must adhere to ECs. This process of mural cell recruitment is triggered mainly by platelet-derived growth factor-B produced by ECs. 3 Subsequently, angiopoietin-1 (Ang1) produced by mural cells directly stimulates Tie2, a tyrosine kinase receptor expressed on ECs, resulting in cellto-cell adhesion between mural cells and ECs. 4 --7 Under hypoxia, for induction of angiogenic switching in pre-existing blood vessels, Ang2, an antagonist of Ang1 produced by ECs, inhibits phosphorylation of Tie2, followed by mural cell dissociation from ECs. 8 This process is thought to be essential for initiation of sprouting angiogenesis.
In addition to dissociation of mural cells from ECs, it is believed that transient disruption of the integrity of cell-to-cell binding is required to induce angiogenesis via transcellular extravasation into ischemic or inflammatory foci of proangiogenic hematopoietic cells as an accessory cell component. 9 EC-to-EC contact is regulated by different adhesion molecules, among which vascular endothelial (VE)-cadherin in particular plays essential roles in the formation of adherens junctions and in permeability control. 10 It was shown to be essential for the formation of stable blood vessels 11 --13 and is also important for EC tube formation, inducing tube-like structures even when expressed in melanoma tumor cells.
14 Phosphorylation or endocytosis of VE-cadherin induced by activation of the VEGF receptor has been suggested to attenuate barrier function of ECs for leukocyte transmigration through the EC monolayer. 9 However, whether the transcription or translation of VE-cadherin is affected by VEGF has not been well established.
MicroRNAs (miRNAs or miRs) are endogenous short noncoding RNAs regulating gene expression either through translational inhibition or destabilization of target mRNA. 15 Crucial roles of miRNAs have been reported for many aspects of development, homeostasis and disease including tumor development. 16 Several lines of evidence suggest the involvement of miRNA in blood vessel formation. 17 Therefore, in the present study, we searched for miRNAs that are transiently endogenously upregulated in ECs on angiogenic switching and could inhibit angiogenesis if continuously overexpressed.
RESULTS
MiR-125b is upregulated in ECs under hypoxia or on stimulation with VEGF and inhibits their in vitro tube formation We first analyzed the expression of miRs in ECs from hindlimb muscle subjected to hypoxia by the occlusion of the femoral artery. At 1 day after induction of ischemia, primary ECs (CD31 þ CD45 À ) from hindlimb muscles of mice were isolated by fluorescenceactivated cell sorting. ECs from hindlimb muscle in the steady state acted as controls to compare the expression of miRs. Based on earlier reports of which miRs are expressed in ECs under different conditions, 17 we evaluated the expression of 20 miRs using quantitative reverse-transcription real-time PCR (qRT --PCR) analysis. Of these, we found that miRs 15b, 20b, 29a, 99a, 100, 103, 106b, 125b, 191 and 222 were increased by hypoxia ( Figure 1a ). We hypothesized that tumor cells may negatively regulate miRs that induce regression of blood vessels. Of the miRs overexpressed in ECs under tissue hypoxia, miRs 29a, 103 and 125b have been reported to be decreased in co-culture with tumor cells. 18 Here, we investigated the function of these miRs, as well as of miR-181a, which decreased in ECs either on hindlimb ischemia or co-culture with tumor cells, using in vitro tube formation of human umbilical vein ECs (HUVECs) as a readout. The results suggest that only miR125b inhibits tube formation (Figure 1b) . Therefore, we focused on miR-125b to study associations with angiogenesis.
Because miR-125b is upregulated in primary ECs under tissue hypoxia, we established the kinetics of its expression compared with miR-92a, which has been reported to be upregulated in ECs upon tissue hypoxia, 19 and snoRNA202, which is widely used as a nonregulated gene in various tissues. As shown in Figure 1c , miR125b expression was transiently increased in ECs at 1 day after induction of ischemia and returned to basal level from day 2. miR-92a was also increased 1 day after induction of ischemia and gradually decreased thereafter.
Next, we assessed the expression of miR-125b in cultured HUVECs and tested whether this miR is upregulated upon angiogenic stimuli or hypoxia. First, we quantified the expression of miR-125b compared with miR-126, which is abundantly expressed specifically in ECs, 20 as well as with other miRs (Supplementary Figure S1) . We found that miR125b is not highly expressed in HUVECs under the usual culture conditions. However, as with tissue hypoxia in vivo, we found that pro-angiogenic VEGF stimulation, as well as hypoxia (1.5% O 2 ), transiently induced miR125b expression in cultured HUVECs (Figure 2a) . VEGF is upregulated in ECs under tissue hypoxia. Therefore, hypoxiamediated VEGF production in HUVECs may itself directly induce miR125b. However, hypoxia-induced miR125b is expressed earlier than VEGF in HUVECs, suggesting that other molecular cues associated with hypoxia induce miR125b. Moreover, basic fibroblast growth factor, a known pro-angiogenic factor, also induced miR-125b expression. Taken together, these data suggest the involvement of several growth factors for induction of miR125b under conditions of tissue hypoxia similar to those that induce angiogenesis.
As recently reported, VEGF enhances the expression of p53, 21 and because several miRs are induced by p53 with the Drosha complex, 22, 23 we tested whether miR125b expression is regulated by p53 in ECs. Small interfering RNA-mediated p53 knockdown inhibited VEGF-mediated induction of miR125b as well as constitutive expression of this miR (Figure 2b and Supplementary Figure S2 ). MiR-125b inhibits translation of VE-cadherin mRNA It has been reported that miR-125b suppresses the expression of Her2 (human epidermal growth factor receptor-related 2) and Bak1 (BCL2-antagonist/killer 1), 24, 25 but there are no reports on angiogenesis-related gene expression regulation by miR-125b. We employed several miR target prediction algorithms to identify putative miR-125b targets. We identified VE-cadherin as a target with a potential conserved binding site within its 3 0 untranslated region (3 0 UTR) screened by TargetScan (Whitehead Institute for Biomedical Research, Cambridge, MA, USA); this sequence is evolutionarily conserved (Figure 3a ). VE-cadherin is involved in tube formation by ECs by providing the adhesive component of endothelial adherens junctions.
2,9,10 Based on our results on tube formation in matrigel (Figure 1b) , we hypothesized that miR-125b might downregulate synthesis of VE-cadherin by directly binding to sites within the 3 0 UTR of its message. To assess this possibility, we constructed luciferase reporter vectors encoding the complete wild-type 3 0 UTR of VE-cadherin mRNA as well as parallel control vectors containing mismatches in the predicted miR-125b binding site, or luciferase vectors containing no VE-cadherin UTR. As shown in Figure 3b , co-transfection of miR-125b with the luciferase reporter gene linked to the wild-type 3 0 UTR of human or mouse VE-cadherin resulted in a significant decrease in luciferase activity. In contrast, co-transfection of miR-125b with constructs containing mutated 3 0 UTR sequences did not result in decreased luciferase activity.
To confirm miR-125b-mediated modulation of endogenous VE-cadherin in ECs, HUVECs were transfected with miR-125b or control miR and expression of VE-cadherin on HUVECs assessed by western blotting and flow cytometry. An B60% decrease of VE-cadherin expression resulted from the induction of miR-125b, using precursor molecules (pre-miR) (Figures 3c and d) . We confirmed a reduction of cell surface VE-cadherin expression by flow cytometry (Figure 3e ). We could not detect any alteration of VE-cadherin mRNA expression caused by miR-125b ( Figure 3f ). Indeed, inhibition of tube formation by miR-125b was abrogated by the overexpression of VE-cadherin (Figures 4a and b and Supplementary Figure S3) ; miR-125b inhibition did not enhance VE-cadherin expression (data not shown).
MiR-125b inhibits tumor growth mediated by severe hypoxia through disruption of EC tube formation The results described above suggested that introduction of miR125b into the tumor would inhibit angiogenesis and tumor growth. Before assessing the in vivo anti-angiogenic effect of injecting miR-125b into tumors, we tested its effects on tumor cells in vitro.
Although it had been previously reported that miR-125b attenuated ErbB2 (erythroblastic leukemia viral oncogene homolog 2) expression and decreased proliferation of breast cancer cells in vitro, 24 our experiments failed to demonstrate any inhibitory effects of miR-125b on these parameters in Lewis lung carcinoma (LLC) or colon-26 cancer cells (Supplementary Figure S4) .
We inoculated mice subcutaneously with tumor cells and started to inject miR-125b directly into the tumor using non-viral vectors composed of the cationic polymer polyethylenimine Figure S5a and b) , but there were no differences between control and anti-miR-125-treated groups. In the group treated with anti-miR-125b, tumor growth might have been expected to increase compared with control because of the possibility of VE-cadherin expression enhancement. However, antimiR-125b treatment did not markedly enhance VE-cadherin expression in the tumor environment. Moreover, we confirmed that enhancement of VE-cadherin expression was also not induced in HUVECs by anti-miR-125b transfection. Our study suggests that the level of miR-125b expression in tumor ECs is slightly upregulated (o2.0-fold) but is not markedly higher than in ECs in normal skin, and that its localization therein is random, with no specific expression profile (data not shown). Therefore, antimiR-125b may not enhance VE-cadherin expression in the tumor.
Real-time RT --PCR analysis confirmed significantly higher levels of miR-125b expression in tumors injected with miR-125b ( Figure 5c and Supplementary Figure S5c) . Essentially all CD31 þ ECs in control tumors expressed VE-cadherin, but in the miR-125b-transfected tumors, VE-cadherin expression by the majority of CD31 þ ECs was greatly reduced around the area of miR-125b injection (Supplementary Figure S6) . Analysis of single-cell suspensions from each tumor confirmed the attenuation of endothelial VE-cadherin expression in miR-125b-injected tumors compared with controls ( Figure 5d ).
The miR-125b treatment significantly reduced the number of blood vessels in the tumor, but the difference was not marked (Figures 6a and b) . On the other hand, morphological studies revealed indented irregular shaped blood vessels in miR-125b-injected tumors, not seen in controls. Moreover, we commonly found blood vessels stained with CD31 in miR-125b-treated tumors that were not stained by in vivo lectin perfusion, indicating lack of blood flow through them (Figure 6a ). Assessing the state of 5 HUVECs in six-well culture plates were serum starved for 6 h by culturing in Humedia EG2 without growth factors, and cultured in the presence or absence of VEGF (10 ng/ml) or basic fibroblast growth factor (bFGF; 5 ng/ml) or under hypoxic conditions (1.5% O 2 ) for the indicated times. miR-125b expression level by qRT --PCR was normalized to RNU6 using the comparative threshold cycle method. Level of miR-125b expression before stimulation with several factors was set as one. *Po0.01, **Po0.05 (n ¼
hypoxia using hypoxyprobe showed that miR-125b-treated tumors were more hypoxic than controls (Figures 7a and b) . Therefore, we concluded that miR-125b-suppressed VE-cadherin expression in ECs resulted in inhibition of tube formation, and because severe hypoxia is thus induced in the tumor environment, miR-125b inhibits tumor growth.
DISCUSSION
Here we report that miR-125b is upregulated in hypoxic ECs or on stimulation with VEGF or basic fibroblast growth factor. p53 is a regulator of miR-125b induction, but other mechanisms regulating its expression are also likely to exist. miR-125b binds directly to the 3 0 UTR of VE-cadherin mRNA and inhibits its translation. In contrast to upregulation of miR-125b expression, miR-125a was downregulated in ECs upon hypoxia. The seed sequences of miR-125a and miR-125b are identical, and downregulation of miR-125a may affect VE-cadherin expression; however, we focused on miR-125b, because we were seeking miRs that were upregulated and affected angiogenesis upon hypoxia.
When miR-125b is induced in ECs, their in vitro tube formation is suppressed by a mechanism involving inhibition of VE-cadherin expression. This is confirmed by the finding that preceding overexpression of VE-cadherin in ECs prevents this suppression of tube formation by miR-125b. By blocking VE-cadherin expression in tumor ECs, miR-125b inhibited tumor outgrowth by disrupting EC tube formation. Although our studies have focused on ECs, we cannot completely exclude the possibility that miR-125b also affects other cell types in the tumor environment. However, as far as we could determine, miR-125b had no effect on tumor cell proliferation itself.
Induction of miR-125b expression in ECs of ischemic hindlimb muscle is transient, suggesting that miR-125b may have a role at the onset of angiogenesis in loosening EC contacts to allow extravasation of proangiogenic hematopoietic cells or bone marrow vascular progenitors into ischemic foci. We previously reported that many hematopoietic cells infiltrate into tumor sites from the edge of the tumor and that inhibition of migration of hematopoietic cells into the tumor inhibited tumor angiogenesis. 27 It is well known that hematopoietic cells can exert proangiogenic activity as an accessory cell component and that infiltration of these cells into the tumor environment occurs before ECs form blood vessels in the tumor. 27 ,28 Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) is a phosphatase suppressing phosphorylation of VE-cadherin. Lack of VE-PTP leads to constitutive activation of VE-cadherin, resulting in suppression of normal angiogenesis. 29 Suppression of VEcadherin function enhances the extravasation of hematopoietic cells. 30 Interestingly, pretreatment with anti-miR-125b in a tumor xenograft model led to retardation of tumor growth (Supplementary Figure S7 ). Moreover, preinduction of anti-miR-125b in HUVECs led to suppression of endothelial sprouting in a model using endothelial spheroids (Supplementary Figure S8) . These findings suggest that transient downregulation of VE-cadherin expression is required for initiation of angiogenesis and that miR125b may be involved in this process. However, further analysis is required to clarify the physiological function of miR-125b.
At the initiation of angiogenesis, it is widely accepted that Ang2, an antagonist of Ang1 that maintains stability of blood vessels by cell-to-cell adhesion between mural cells and ECs through the Tie2 receptor, is released from ECs to destabilize the vessels. 7, 8 Hence, transient Ang2 expression is required for initiating angiogenesis, but its prolonged expression results in blood vessel regression under physiological or pathological conditions. 31 Thus far, no molecules other than Ang2 participating in transient destabilization of preexisting blood vessels have been identified. As tissue hypoxia or VEGF induces miR-125b expression in ECs, this miR may be involved in the initiation of angiogenesis by suppression of VE-cadherin expression. Although it is possible that the antiangiogenic factor miR-125b is merely upregulated upon stimulation by pro-angiogenic factors as a negative feedback mechanism, but is not required for initiation of sprouting angiogenesis, our data suggest that excessively prolonged miR-125b expression prevents EC tube formation, leading to inhibition of tumor growth as observed in the Tie2/Ang2 system.
Our study suggests that ECs in the tumor environment express a little more miR-125b than other ECs. Nonetheless, the level of expression of miR125b was not particularly high, as described above. This is consistent with our initial hypothesis that tumor cells suppress expression of molecules in the tumor environment, which would mitigate against tumor growth. Indeed, when HUVECs were co-cultured with tumor cells, miR-125b expression was downregulated. Although this finding has already been reported by another group, 18 we found that VEGF co-stimulation in co-cultures of HUVECs and tumor cells resulted in slightly upregulated miR125b expression in the former. However, the level of expression of this miR did not exceed the original level in HUVECs (Supplementary Figure S9) . Therefore, tumor cell-derived factors must oppose VEGF effects for upregulation of miR-125b in ECs.
Molecular analysis of miRs has progressed rapidly and application of miRs in cancer therapy is being considered. One line of evidence showed involvement of miR-92a in vascular integrity by means of regulating the integrin subunit a-5, known to play an important role in angiogenesis. 19 It is suggested that ) were inoculated subcutaneously into C57BL/6 mice. Anti-miR, anti-miR-125b; n.c., negative control; premiR, miR-125b. (b) Tumor growth suppressed by miR-125b but not by anti-miR-125b. Arrows indicate the day of miR injection. Tumor growth was monitored by calculating tumor volume on days 10, 12, 14, 17 and 19 after injection of miR-125 (pre-miR), anti-miR-125b (anti-miR) or negative control (control). *Po0.05 (n ¼ 3). (c) Detection of miR-125b expression in the tumor. At 2 days after injection of miR-125b, total RNA from tumor was isolated. A 3.5-fold increased level of miR-125b in the miR-125 (pre-miR)-injected group compared with the control miR (n.c.) group is seen. Anti-miR-125b suppressed the endogenous expression of miR-125b. Values normalized to RNU6 expression in each tumor were compared with the values obtained from the n.c. set at unity. *Po0.01 (n ¼ 3). (d) Suppression of VE-cadherin expression on ECs in the tumor. Single-cell suspensions from tumors injected with control miR (n.c.) or miR-125b (pre-miR) as described in (a) were stained with anti-VE-cadherin and anti-CD31 monoclonal antibodies (mAbs) and analyzed by flow cytometry. VE-cadherin expression on CD31-positive cells was analyzed. Mean intensity of VE-cadherin expression in these two groups was significantly different (Po0.05, n ¼ 5). The data shown are representative.
Negative regulation of angiogenesis by mir-125b F Muramatsu et al overexpression of miR-92a inhibits angiogenesis by attenuating a-5 integrin expression in ischemic tissue. We found that miR92a is also transiently upregulated in ECs upon tissue hypoxia. Taken together with the results of the miR-125b study, it is suggested that miRNAs upregulated in ECs at the onset of angiogenesis may have an anti-angiogenic function; thus, it may be useful to identify anti-angiogenic miRs by this method. Using delivery of miRs directly into ECs in the tumor environment, miR-125b should be a good candidate for inhibition of tumor angiogenesis.
MATERIALS AND METHODS

Animals and cells
C57BL/6 mice were purchased from Japan SLC (Shizuoka, Japan). Animals were housed in environmentally controlled rooms of the animal experimentation facility at Osaka University. All experiments were carried out following the guidelines of Osaka University Committee for animal and recombinant DNA experiments. HUVECs (Kurabo, Osaka, Japan) were cultured in Humedia EG2. HUVECs were grown to confluence, serum starved and stimulated with VEGF (10 ng/ml; PeproTech, Rocky Hill, NJ, USA). Analyses such as of tube formation were performed as described.
32
LLC cells were maintained in Dulbecco's modified Eagle's medium (Sigma, St Louis, MO, USA) with 10% fetal bovine serum (Sigma) and penicillin/ streptomycin (GIBCO, Rockville, MD, USA). A murine hindlimb ischemia model was established by the occlusion of the femoral artery as previously reported. 33 Sorting of primary ECs (CD31 þ CD45 À ) from hindlimb muscle or tumor tissues was performed using a JSAN flow cytometer (Bay Bioscience, Kobe, Japan) as reported previously. 32 Tumor cell xenograft model was also as previously reported. 34 Preparation of single-cell suspensions from tumors and flow cytometric analysis were performed as previously described. 35 Quantitative reverse-transcription real-time PCR For miRs assessments, total RNA was extracted using PureLink miRNA Isolation Kits (Invitrogen, Carlsbad, CA, USA) and subjected to reverse transcription with the NCode miRNA First-Strand cDNA Synthesis and qRT --PCR Kits (Invitrogen) according to the manufacturer's instructions. qRT --PCR was performed with the Mx3000P QPCR System (Agilent Technologies Inc., Santa Clara, CA, USA) using Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen). Results were normalized to RNU6 using the comparative threshold cycle method. Specific primers used in this experiment are described in Supplementary Table S1 .
For detection of mRNA, total RNA was extracted using RNeasy mini kits (QIAGEN, Valencia, CA, USA) and reverse transcribed using the PrimeScript RT reagent Kit (Takara, Otsu, Japan) according to the manufacturer's instructions. qRT --PCR was performed as described above. Results were normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) with the comparative threshold cycle method. Specific primers used in this experiment were as follows: human VE-cadherin: Transfection of plasmid, RNA interference and miRNA For overexpression of miRs, 33 nM pre-miRs 125-b, 29a, 103 and 181a or pre-miR-control (Applied Biosystems, Foster City, CA, USA) were transfected into HUVECs using Lipofectamine 2000 (Invitrogen). After 5 h, the cells were cultured in Humedia EG2 until further analysis. For knockdown of p53, small interfering RNA (TP53 stealth select RNA interference; Invitrogen) or control small interfering RNA (Invitrogen) was introduced into HUVECs as described above. For the rescue experiment of VE-cadherin, the human VE-cadherin expression vector (a kind gift of Dr Fukuhara, NCVC, Osaka, Japan) was introduced into HUVECs with or without pre-miRs-125b, as described above.
In the tumor xenograft model, three million LLC cells were directly injected subcutaneously into the back flanks of 6-week-old female C57BL/6 mice. On days 10, 12, 14 and 17, we injected 400 pM control miR, pre-miR-125b or anti-miR-125b inhibitor (Applied Biosystems) using in vivo-jetPEI 26 (Polyplus Transfection, Illkirch, France) directly into the tumor mass. Measurements of tumor volume were performed as described previously. 35 Tumors were dissected for isolation of miRs and for immunofluorescence analysis 19 days after tumor cell inoculation.
Luciferase assays The 3 0 UTR segments of human and mouse VE-Cadherin predicted to interact specifically with miR-125b were subcloned by standard procedures into the pMIR-REPORT Luciferase vector (Applied Biosystems) immediately downstream of the stop codon of the luciferase gene. In brief, we generated those oligos as follows: human VE-cadherin 3 0 UTR sense oligo ( terminal and with the BamH1/HindIII at the 5 0 terminal, and mouse VE-cadherin 3 0 UTR mut (mutated sequences underlined) antisense oligo (5 0 -AGCTTGGATCCGCCCTGGGGGTGAGGTTCATGTTTGAAGATGTGGCAACT AGGCAAAAGGCGAGTGGCGTGA-3 0 ) ligated with the BamH1/HindIII site at the 3 0 terminal and with Spe1 at the 5 0 terminal. Double-stranded oligos were generated by annealing with sense and anti-sense oligos by standard methods and ligated into Spe1 and HindIII sites of the multiple cloning site of the pMIR-REPORT Luciferase vector. The vectors containing wild-type VE-cadherin or variant 3 0 UTR were transfected into HEK293 cells with or without miR-125b using Lipofectamine 2000. At 48 h after transfection, cells were lysed and luciferase activity was measured (POWERSCAN HT, DS Pharma Biomedical, Osaka, Japan). We used pMIR-REPORT b-gal control plasmid (Applied Biosystems) or pRL-TK plasmid (Promega, Madison, WI, USA) for normalization of luciferase values and the Dual-Glo Luciferase Assay System (Promega) for detection of luciferase activity.
Western blotting
Western blotting using anti-human VE-cadherin antibody was performed as previously described. 32 HUVECs were lysed 48 h after transfection with miR-125b or control miR.
Immunofluorescence
Tumor sections were stained with anti-mouse CD31 (Pharmingen, San Diego, CA, USA) and anti-mouse CD144 (VE-cadherin) antibody (BD Bioscience, San Diego, CA, USA). The procedure for tissue preparation and staining was as previously reported. 36 Lectin staining was performed as previously described 33 using fluorescein isothiocyanate-isolectin (Vector Lab, Burlingame, CA, USA). Hypoxic areas were identified by the fluorescein isothiocyanate-conjugated Hypoxyprobe-1 Mab1 (Natural Pharmacia International, Research Triangle Park, NC, USA). Samples were visualized using conventional microscopy (with a DM5500B equipped with HCX PL FLVOTAR 5/0.15 and HCX PL FLVOTAR 10/0.15 dry objective lenses; Leica, Solms, Germany) or confocal microscopy (Leica). Images were acquired with a DFC 500 digital camera (Leica) and processed with the Leica application suite (Leica) and Adobe Photoshop CS3 software (Adobe Systems, San Jose, CA, USA). All images shown are representative of 3 --5 independent experiments.
Statistical analysis
All data were displayed as the mean ± s.d. and were analyzed by repeatedmeasures two-way analysis of variance or Student's t-test using Statview software (Abacus Concepts, Berkeley, CA, USA). A probability value of o0.05 was considered statistically significant.
